Advances in human papilloma virus vaccines: a patent review

Bibliography

• D'Andrilli G, Bovicelli A, Giordano A. HPV vaccines: state of the art. J Cell Physiol 2010;224(3):601-4
   PubMed Web of Science ®Google Scholar
• Bermudez-Humaran LG, Langella P. Perspectives for the development of human papillomavirus vaccines and immunotherapy. Expert Rev Vaccines 2010;9(1):35-44
   PubMed Web of Science ®Google Scholar
• Munoz N, Bosch FX, de Sanjose S, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;21(6):518-27
   Google Scholar
• Harper DM. Currently approved prophylactic HPV vaccines. Expert Rev Vaccines 2009;8(12):1663-79
   PubMed Web of Science ®Google Scholar
• Stanley MA. Human papillomavirus vaccines. Rev Med Virol 2006;16(3):139-49
   PubMed Web of Science ®Google Scholar
• McNeil C. Who invented the VLP cervical cancer vaccines? J Natl Cancer Inst 2006;98:433
   PubMedGoogle Scholar
• Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991;185(1):251-7
   PubMed Web of Science ®Google Scholar
• Ghim SJ, Jenson AB, Schlegel R. HPV-1 L1 protein expressed in cos cells displays conformational epitopes found on intact virions. Virology 1992;190(1):548-52
   PubMed Web of Science ®Google Scholar
• Kirnbauer R, Booy F, Cheng N, Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992;89(24):12180-4
   PubMed Web of Science ®Google Scholar
• Rose RC, Bonnez W, Reichman RC, Garcea RL. Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J Virol 1993;67(4):1936-44
   PubMed Web of Science ®Google Scholar
• Padmanabhan S, Amin T, Sampat B, Intellectual property, technology transfer and manufacture of low-cost HPV vaccines in India. Nat Biotechnol 2010;28(7):671-8
   PubMed Web of Science ®Google Scholar
• GlaxoSmithkline, Biolog SA. HPV-16 and -18 L1 VLP vaccine. WO2004056389; 2004
   Google Scholar
• GlaxoSmithkline, Biolog SA. Vaccine against HPV 16 and HPV 18 and at least another HPV types selected from 31, 45 or 52. WO2005123125; 2005
   Google Scholar
• GlaxoSmithkline, Biolog SA. Vaccine. WO2006114312; 2006
   Google Scholar
• Merck & Co., Inc. Optimized expression of HPV 31 L1 in yeast. WO200408483; 2004
   Google Scholar
• Merck & Co., Inc. Optimized expression of HPV 45 L1 in yeast. WO2005032586; 2005
   Google Scholar
• Merck & Co., Inc. Optimized expression of HPV 52 L1 in yeast. WO2005097821; 2005
   Google Scholar
• Merck & Co., Inc. Optimized expression of HPV 58 L1 in yeast. WO2005047315; 2005
   Google Scholar
• Indian Immunologicals Ltd. Codon-optimized HPV16 L1 for salmonella vaccine strains against human papillomavirus type 16. WO2005123762; 2005
   Google Scholar
• Univ Konkuk Ind. Coop. Corp. Baculovirus-based vaccines. WO2009088256; 2009
   Google Scholar
• Univ Cape Town. Chimeric human papillomavirus 16 L1 proteins comprising an L2 peptide,virus-like particles prepared therefrom and a method for preparing the particles. EP1506222; 2009
   Google Scholar
• Loyola University Chicago. Papilloma virus capsomere vaccine formulations and methods of use. US7754430; 2010
   Google Scholar
• Shi L, Sings HL, Bryan JT, GARDASIL: prophylactic human papillomavirus vaccine development–from bench top to bed-side. Clin Pharmacol Ther 2007;81:259-64
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline Vaccine HPV-007 Study Group, Romanowski B, de Borba PC, Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009;374(9706):1975-85
   PubMed Web of Science ®Google Scholar
• Brandsma JL, Shylankevich M, Su Y, Vesicular stomatitis virus-based therapeutic vaccination targeted to the E1, E2, E6, and E7 proteins of cottontail rabbit papillomavirus. J Virol 2007;81(11):5749-58
   PubMed Web of Science ®Google Scholar
• Monie A, Tsen SW, Hung CF, Wu TC. Therapeutic HPV DNA vaccines. Expert Rev Vaccines 2009;8(9):1221-35
   PubMed Web of Science ®Google Scholar
• Wu CY, Monie A, Pang X, Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation. J Biomed Sci 2010;17(1):88
   PubMedGoogle Scholar
• Li M, Cripe TP, Estes PA, Expression of the human papillomavirus type 11 L1 capsid protein in Escherichia coli: characterization of protein domains involved in DNA binding and capsid assembly. J Virol 1997;71(4):2988-95
   PubMed Web of Science ®Google Scholar
• Senger T, Schadlich L, Gissmann L, Muller M. Enhanced papillomavirus-like particle production in insect cells. Virology 2009;388(2):344-53
   PubMed Web of Science ®Google Scholar
• Hagensee ME, Yaegashi N, Galloway DA. Self-assembly of human papillomavirus type 1 capsids by expression of L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol 1993;67:315-22
   PubMed Web of Science ®Google Scholar
• Hofmann KJ, Neeper NP, Markus HZ, Sequence conservation within the major capsid protein of human papillomavirus (HPV) type 18 and formation of HPV-18 viruslike particles in Saccharomyces cerevisiae. J Gen Virol 1996;77:465-8
   PubMed Web of Science ®Google Scholar
• Neeper MP, Hofmann KH, Jansen KU. Expression of the major capsid protein of human papillomavirus type 11 in Saccharomyces cerevisiae. Gene 1996;180:1-6
   PubMed Web of Science ®Google Scholar
• Giorgi C, Franconi R, Rybicki EP. Human papillomavirus vaccines in plants. Expert Rev Vaccines 2010;9:913-24
   PubMed Web of Science ®Google Scholar
• Waheed MT, Thones N, Muller M, Transplastomic expression of a modified human papillomavirus L1 protein leading to the assembly of capsomeres in tobacco: a step towards cost-effective second-generation vaccines. Transgenic Res 2010. [Epub ahead of print]
   Google Scholar
• Demain AL, Vaishnav P. Production of recombinant proteins by microbes and higher organisms. Biotechnol Adv 2009;27(3):297-306
   PubMed Web of Science ®Google Scholar
• Hatfield GW, Roth DA. Optimizing scaleup yield for protein production: computationally Optimized DNA Assembly (CODA) and translation engineering. Biotechnol Annu Rev 2007;13:27-42
   PubMedGoogle Scholar
• McNulty DE, Claffee BA, Huddleston MJ, Mistranslational errors associated with the rare arginine codon CGG in Escherichia coli. Protein Expr Purif 2003;27:365-74
   PubMed Web of Science ®Google Scholar
• Sorensen HP, Mortensen KK, Advanced genetic strategies for recombinant protein expression in Escherichia coli. J Biotechnol 2005;115:113-28
   PubMed Web of Science ®Google Scholar
• Mossadegh N, Gissmann L, Muller M, Codon optimization of the human papillomavirus 11 (HPV 11) L1 gene leads to increased gene expression and formation of virus-like particles in mammalian epithelial cells. Virology 2004;326(1):57-66
   PubMed Web of Science ®Google Scholar
• Maclean J, Koekemoer M, Olivier AJ, Optimization of human papillomavirus type 16 (HPV-16) L1 expression in plants: comparison of the suitability of different HPV-16 L1 gene variants and different cell-compartment localization. J Gen Virol 2007;88:1460-9
   PubMed Web of Science ®Google Scholar
• Carter JJ, Yaegashi N, Jenison SA, Galloway DA. Expression of human papillomavirus proteins in yeast Saccharomyces cerevisiae. Virology 1991;182(2):513-21
   PubMed Web of Science ®Google Scholar
• Park DS, Selvey LA, Kelsall SR, Frazer IH. Human papillomavirus type 16 E6, E7 and L1 and type 18 E7 proteins produced by recombinant baculoviruses. J Virol Methods 1993;45(3):303-18
   PubMed Web of Science ®Google Scholar
• Reinstein E, Scheffner M, Oren M, Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: targeting via ubiquitination of the N-terminal residue. Oncogene 2000;19(51):5944-50
   PubMed Web of Science ®Google Scholar
• Csl Ltd. Papillomavirus polyprotein constructs. US6365160; 2002
   Google Scholar
• Enea Ente Nuove Tec. Subunit vaccines and processes for the production thereof. EP1401493; 2007
   Google Scholar
• Kadish AS, Einstein MH. Vaccine strategies for human papillomavirus-associated cancers. Curr Opin Oncol 2005;17(5):456-61
   PubMed Web of Science ®Google Scholar
• Kawana K, Yasugi T, Taketani Y. Human papillomavirus vaccines: current issues & future. Indian J Med Res 2009;130(3):341-7
   PubMed Web of Science ®Google Scholar
• MediGene AG. Papillomavirus truncated L1 protein and fusion protein constructs. US6649167; 2003
   Google Scholar
• Lin CT, Chang TC, Chao A, Enhancement of DNA vaccine potency through linkage of antigen gene to ER chaperone molecules, ER-60, tapasin, and calnexin. J Biomed Sci 2005;12(2):279-87
   PubMed Web of Science ®Google Scholar
• Sunbio Biotech Pharmaceuticals, HPV antigen fusion protein vaccine compositions and uses thereof. WO2008049329; 2008
   Google Scholar
• GlaxoSmithkline, Biolog SA. Vaccine against HPV. EP1007551; 2004
   Google Scholar
• Christensen ND, Reed CA, Cladel NM, Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV 11 in addition to typespecific epitopes on HPV-6. Virology 1996;224:477-86
   PubMed Web of Science ®Google Scholar
• White WI, Wilson SD, Bonnez W, In vitro infection oftype-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. J Virol 1998;72:959-64
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline Biologicals SA. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52. WO2005123125; 2005
   Google Scholar
• Smithkline Beecham Corp. Vaccine against HPV. WO2008145745; 2008
   Google Scholar
• Novartis Vaccines and Diagnostics, Inc. Method for producing yeast expressed HPV types 6 and 16 capsid proteins. US7494787; 2009
   Google Scholar
• Sasagawa T, Pushko P, Steers G, Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe. Virology 1995;206(1):126-35
   PubMed Web of Science ®Google Scholar
• Johns Hopkins University. Papillomavirus L2 N-terminal peptides for the induction of broadly cross-neutralizing antibodies. US20090047301; 2009
   Google Scholar
• Jagu S, Karanam B, Gambhira R, Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst 2009;101:782-92
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline Biologicals SA. Novel composition. WO2002087614; 2002
   Google Scholar
• GlaxoSmithKline Biologicals SA. Vaccine composition comprising herpes simplex virus and human papilloma virus antigens. US6936255; 2005
   Google Scholar
• GlaxoSmithKline Biologicals SA. Vaccine against hbv and hpv. EP1731167; 2008
   Google Scholar
• Smithkline Beecham Biolog. Vaccine against HBV and HPV. US7371390; 2008
   Google Scholar
• Wheeler CM, Bautista OM, Tomassini JE, Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine 2008;26(5):686-96
   PubMed Web of Science ®Google Scholar
• Warzecha H, Mason HS, Lane C, Oral immunogenicity of human papillomaviruslike particles expressed in potato. J Virol 2003;77:8702-11
   PubMed Web of Science ®Google Scholar
• Biemelt S, Sonnewald U, Galmbacher P, Production of human papillomavirus type 16 virus-like particles in transgenic plants. J Virol 2003;77(17):9211-20
   PubMed Web of Science ®Google Scholar
• Cho HJ, Shin HJ, Han IK, Induction of mucosal and systemic immune responses following oral immunization of mice with Lactococcus lactis expressing human papillomavirus type 16 L1. Vaccine 2007;25(47):8049-57
   PubMed Web of Science ®Google Scholar
• Asahi Glass Co. Ltd. Edible vaccine. US20090017063; 2009
   Google Scholar
• Asahi Glass Co. Ltd. Edible vaccine. Human papilloma virus vaccine for oral administration. EP1790332; 2010
   Google Scholar
• Sasagawa T, Tani M, Basha W, A human papillomavirus type 16 vaccine by oral delivery of L1 protein. Virus Res 2005;110(1-2):81-90
   PubMed Web of Science ®Google Scholar
• Bioleaders Corp. Vector for treatment vaccine for stable and constitutive high-expression cervical cancer and recombinant Lactobacillus transformed by the same. WO2010079991; 2010
   Google Scholar
• Genomine, Inc. Recombinant human papillomavirus vaccine expressed in transgenic plants. US6444805; 2002
   Google Scholar
• Varmus H, Klausner R, Zerhouni E, Public health grand challenges in grobal health. Science 2003;302:398-99
   PubMed Web of Science ®Google Scholar
• Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol 2008;26(11):1261-8
   PubMed Web of Science ®Google Scholar
• Mitragotri S. Immunization without needles. Nat Rev Immunol 2005;5:905-16
   PubMed Web of Science ®Google Scholar
• Felotn medical, Inc. Disposable unit-dose jet-injection syringe for pre-filled and/or transfilled liquid injectable medical drug or vaccine products and method thereof. US6610042; 2003
   Google Scholar
• Han R, Peng XW, Reed CA, Gene gun-mediated intracutaneous vaccination with papillomavirus E7 gene delays cancer development of papillomavirus-induced skin papillomas on rabbits. Cancer Detect Prev 2002;26:458-67
   PubMedGoogle Scholar
• Matthews K, Rhind SM, Gossner AG, The effect of gene gun-delivered pGM-CSF on the mmunopathology of the vaccinated skin. Scand J Immunol 2007;65(3):298-307
   PubMed Web of Science ®Google Scholar
• Bioware Technology Co. Ltd. Low pressure gas accelerated gene gun. US7638332; 2009
   Google Scholar
• Sivamani RK, Liepmann D, Maibach HI. Microneedles and transdermal applications. Expert Opin Drug Deliv 2007;4(1):19-25
   PubMed Web of Science ®Google Scholar
• Matriano JA, Cormier M, Johnson J, Macroflux microprojection array patch technology: a new and efficient approach for intracutaneous immunization. Pharm Res 2002;19(1):63-70
   PubMed Web of Science ®Google Scholar
• De Magistris MT. Mucosal delivery of vaccine antigens and its advantages in pediatrics. Adv Drug Deliv Rev 2006;58(1):52-67
   PubMed Web of Science ®Google Scholar
• Lavelle EC. Generation of improved mucosal vaccines by induction of innate immunity. Cell Mol Life Sci 2005;62(23):2750-70
   PubMed Web of Science ®Google Scholar
• Singh M, Briones M, O'Hagan DT. A novel bioadhesive intranasal delivery system for inactivated influenza vaccines. J Control Release 2001;70(3):267-76
   PubMed Web of Science ®Google Scholar
• Chiron Corp. Use of hyaluronic acid polymers for mucosal delivery of vaccine and adjuvants. US6824793; 2004
   Google Scholar
• Han IK, Kim YB, Kang HS, Thermosensitive and mucoadhesive delivery systems of mucosal vaccines. Methods 2006;38(2):106-11
   PubMed Web of Science ®Google Scholar
• Park JS, Oh YK, Kang MJ, Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems. J Med Virol 2003;70(4):633-41
   PubMed Web of Science ®Google Scholar
• Cho HJ, Kim JY, Lee Y, Enhanced humoral and cellular immune responses after sublingual immunization against human papillomavirus 16 L1 protein with adjuvants. Vaccine 2010;28(14):2598-606
   PubMed Web of Science ®Google Scholar
• Shahiwala A, Vyas TK, Amiji MM. Nanocarriers for systemic and mucosal vaccine delivery. Recent Pat Drug Deliv Formul 2007;1(1):1-9
   PubMedGoogle Scholar
• Chadwick S, Kriegel C, Amiji M. Delivery strategies to enhance mucosal vaccination. Expert Opin Biol Ther 2009;9(4):427-40
   PubMed Web of Science ®Google Scholar
• Chadwick S, Kriegel C, Amiji M. Nanotechnology solutions for mucosal immunization. Adv Drug Deliv Rev 2010;62(4-5):394-407
   PubMed Web of Science ®Google Scholar
• Garg NK, Mangal S, Khambete H, Mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymers. Recent Pat Drug Deliv Formul 2010;4(2):114-28
   PubMedGoogle Scholar
• Novartis vaccines & Diagnostic. Non-toxic mucosal adjuvant. EP732937; 2009
   Google Scholar
• Medeva Holdings BV. Vaccine compositions for mucosal delivery. EP937462; 2006
   Google Scholar
• Austin Res Inst. Mannose as intranasal vaccine adjuvant. EP1301208; 2010
   Google Scholar
• Lin K, Roosinovich E, Ma B, Therapeutic HPV DNA vaccines. Immunol Res 2010;47(1-3):86-112
   PubMed Web of Science ®Google Scholar
• Univ Johns Hopkins. Molecular vaccine linking an endoplasmic chaperone polypeptide to an antigen. US7342002; 2008
   Google Scholar
• Howe C, Garstka M, Al-Balushi M, Calreticulin-dependent recycling in the early secretory pathway mediates optimal peptide loading of MHC class I molecules. EMBO J 2009;28(23):3730-44
   Google Scholar
• Gold LI, Eggleton P, Sweetwyne MT, Calreticulin: non-endoplasmic reticulum functions in physiology and disease. FASEB J 2010;24(3):665-83
   PubMed Web of Science ®Google Scholar
• Univ Johns Hopkins. Anti-cancer DNA vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin. US20080102084; 2008
   Google Scholar
• Univ Johns Hopkins. HPV DNA vaccines and methods of use thereof. US20080260765; 2008
   Google Scholar
• Glaxo Group Ltd. DNA vaccine encoding at least two nonstructural early proteins of papillomavirus. EP1546191; 2005
   Google Scholar
• Moore RA, Santos EB, Nicholls PK, Intraepithelial DNA immunisation with a plasmid encoding a codon optimised COPV E1 gene sequence, but not the wild-type gene sequence completely protects against mucosal challenge with infectious COPV in beagles. Virology 2002;304(2):451-9
   PubMed Web of Science ®Google Scholar
• Sungkyunkwan University Found. A DNA vaccine for treating or preventing cervical cancer comprising a gene encoding HPV protein. WO2008026869; 2008
   Google Scholar
• Garcia F, Petry KU, Muderspach L, ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2004;103(2):317-26
   PubMed Web of Science ®Google Scholar
• A Study of Amolimogene (ZYC101a) in Patients with High Grade Cervical Intraepithelial Lesions of the Uterine Cervix. FDA Public Health Advisory. Washington, DC: FDA/Center for Drug Evaluation and Research, 2005. Available from: http://clinicaltrials.gov/ct2/show/NCT00264732
   Google Scholar
• Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia. FDA Public Health Advisory. Washington, DC: FDA/Center for Drug Evaluation and Research, 2008. Available from: http://clinicaltrials.gov/ct2/show/NCT00788164
   Google Scholar
• Gabitzsch ES, Xu Y, Yoshida LH, A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses. Immunol Lett 2009;122(1):44-51
   PubMed Web of Science ®Google Scholar
• Gabitzsch ES, Xu Y, Yoshida LH, Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity. Vaccine 2009;27(46):6394-8
   PubMed Web of Science ®Google Scholar
• Beth Israel Hospital. Adenoviral vectors and uses thereof. US7741099; 2010
   Google Scholar
• Bangari DS, Mittal SK. Porcine adenoviral vectors evade preexisting humoral immunity to adenoviruses and efficiently infect both human and murine cells in culture. Virus Res 2004;105(2):127-36
   PubMed Web of Science ®Google Scholar
• Peruzzi D, Dharmapuri S, Cirillo A, A novel chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines. Vaccine 2009;27(9):1293-300
   PubMed Web of Science ®Google Scholar
• Osada T, Yang XY, Hartman ZC, Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity. Cancer Gene Ther 2009;16(9):673-82
   PubMed Web of Science ®Google Scholar
• Deisseroth Albert B. Adenoviral vector vaccine. EP1563074; 2005
   Google Scholar
• Univ Pennsyvania. Simian subfamily C adenoviruses SADV-40, -31, and -34 and uses thereof. WO2009105084; 2009
   Google Scholar
• Univ Groningen. Genetic immunization against cervical carcinoma. US7198792; 2007
   Google Scholar
• Daemen T, Pries F, Bungener L, Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7. Gene Ther 2000;7(21):1859-66
   PubMed Web of Science ®Google Scholar
• GSF Forschungszentrum Umweltus. Modified vaccinia virus Ankara (MVA) mutant and use thereof. US7767209; 2010
   Google Scholar
• Cadila Healthcare Ltd. Combined measles-human papilloma vaccine. WO2010079505; 2010
   Google Scholar
• Cantarella G, Liniger M, Zuniga A, Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma. Vaccine 2009;27(25-26):3385-90
   PubMed Web of Science ®Google Scholar
• Lee HJ, Park N, Cho HJ, Development of a novel viral DNA vaccine against human papillomavirus: AcHERV-HP16L1. Vaccine 2010;28(6):1613-19
   PubMed Web of Science ®Google Scholar
• Univ Pennsylvania. Compositions and methods for enhancing the immunogenicity of antigens. US7588930; 2009
   Google Scholar
• Gunn GR, Zubair A, Peters C, Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol 2001;167(11):6471-9
   PubMed Web of Science ®Google Scholar
• Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 2007;7(3):179-90
   PubMed Web of Science ®Google Scholar
• Ribi ImmunohemReserch, Inc. Aqueous immunogical adjuvant compositions of monophosphoryl lipid A. EP0971739; 2004
   Google Scholar
• Corixa Corp. Aqueous immunogical adjuvant compositions of monophosphoryl lipid A. EP1194166; 2007
   Google Scholar
• Smithkline Beecham Biolog. Adjuvnat systems and vaccines. US7357936; 2008
   Google Scholar
• Ainai A, Ichinohe T, Tamura S, Zymosan enhances the mucosal adjuvant activity of poly(I:C) in a nasal influenza vaccine. J Med Virol 2010;82(3):476-84
   PubMed Web of Science ®Google Scholar
• Dobeel Co. Ltd. A powerful vaccine composition comprising a lipopeptide and poly I:C as an adjuvant. WO2009072767; 2009
   Google Scholar
• Glaxo Group Ltd. Improvements in vaccination. WO2005025614; 2005
   Google Scholar
• Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: an update review. Curr Drug Deliv 2007;4(4):297-305
   PubMedGoogle Scholar
• Klinguer C, Beck A, De-Lys P, Lipophilic quaternary ammonium salt acts as a mucosal adjuvant when co-administered by the nasal route with vaccine antigens. Vaccine 2001;19(30):4236-44
   PubMed Web of Science ®Google Scholar
• Smithkline Beecham Biolog. Oil in water emulsions containing saponins. US7323182; 2008
   Google Scholar
• Statens Seruminstitut. Modified cationic liposome adjuvant. WO2010054654; 2010
   Google Scholar
• GlaxoSmithKline Biologicals S.A. The use of liposomes containing saponins and sterols in the manufacture of intradermal vaccines. EP1432442; 2007
   Google Scholar
• Merck Sharpe & Dohme. Papillomavirus vaccine compositions. US7709010; 2010
   Google Scholar